Marker Therapeutics Inc (MRKR)

[Sugarshaker]

Recent Corporate and Clinical Developments: this was posted one year ago today,

Launched FDA Fast Tracked Phase 2 study in platinum-sensitive ovarian cancer
Completed first safety cohort in Memorial Sloan Kettering-sponsored Phase 2 combination study with AstraZeneca's durvalumab in platinum-resistant ovarian cancer; now more than 50% enrolled
Advanced Phase 2 study in triple-negative breast cancer following safety review
Completed GMP manufacturing scale up and second clinical lot of TPIV 200; to supply additional Phase 2 clinical trials
Announced second U.S. Dept. of Defense-funded Phase 2 breast cancer study; Mayo Clinic to vaccinate women with ductal carcinoma in situ (DCIS) using HER2-targeted T-cell vaccine
Expanded intellectual property for PolyStart™ protein expression platform

What will this year bring........